Ang, Kenny K. H.Ratnam, JoselineGut, JiriLegac, JenniferHansell, ElizabethMackey, Zachary B.Skrzypczynska, Katarzyna M.Debnath, AnjanEngel, Juan C.Rosenthal, Philip J.McKerrow, James H.Arkin, Michelle R.Renslo, Adam R.2018-06-012018-06-012011-05-011935-2727http://hdl.handle.net/10919/83437The targeting of parasite cysteine proteases with small molecules is emerging as a possible approach to treat tropical parasitic diseases such as sleeping sickness, Chagas’ disease, and malaria. The homology of parasite cysteine proteases to the human cathepsins suggests that inhibitors originally developed for the latter may be a source of promising lead compounds for the former. We describe here the screening of a unique ,2,100-member cathepsin inhibitor library against five parasite cysteine proteases thought to be relevant in tropical parasitic diseases. Compounds active against parasite enzymes were subsequently screened against cultured Plasmodium falciparum, Trypanosoma brucei brucei and/or Trypanosoma cruzi parasites and evaluated for cytotoxicity to mammalian cells. The end products of this effort include the identification of sub-micromolar cell-active leads as well as the elucidation of structure-activity trends that can guide further optimization efforts.? - ? (13) page(s)enCreative Commons Attribution 4.0 InternationalInfectious DiseasesParasitologyTropical MedicineCYSTEINE PROTEASE INHIBITORSPLASMODIUM-FALCIPARUMTRYPANOSOMA-BRUCEICHAGAS-DISEASEVINYL SULFONESMOUSE MODELIN-VITRODISCOVERYCRUZIMALARIAArticle - Refereedhttps://doi.org/10.1371/journal.pntd.000102355Mackey, ZB [0000-0002-4533-0973]